Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9718-8
Annals of Surgical Oncology 15:1407-1413 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, L. E.
Right arrow Articles by Saunders, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, L. E.
Right arrow Articles by Saunders, T.

Original Article

Phase I Trial of Pegylated Liposomal Doxorubicin with Hyperthermic Intraperitoneal Chemotherapy in Patients Undergoing Cytoreduction for Advanced Intra-abdominal Malignancy

Lawrence E. Harrison1, Margarette Bryan2, Lilian Pliner2 and Tracie Saunders2

1 Division of Surgical Oncology, UMDNJ—New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA
2 Medical Oncology, UMDNJ—New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA

Correspondence: Address correspondence and reprint requests to: Lawrence E. Harrison; E-mail: L.Harrison{at}umdnj.edu

Background: Cytoreduction coupled with hyperthermic intraperitoneal chemotherapy (HIPEC) is an attractive treatment option for a select group of patients with abdominal-only malignancy. The present phase I study examined the safety and pharmacokinetics of intra-peritoneal pegylated liposomal doxorubicin (PLD) used in the context of HIPEC in patients with advanced abdominal-only malignancies.

Methods: Patients with advanced abdominal malignancies underwent maximal cytoreduction and HIPEC with escalating doses of PLD (15–100 mg/m2). Perfusate, serum, and tissue doxorubicin levels were measured in five patients undergoing HIPEC at the maximum tolerated dose.

Results: Twenty-one patients were enrolled in this trial. The maximum dose evaluated in this trial was 100 mg/m2 and was well tolerated. The most common grade 3/4 complications were superficial wound infection and prolonged ileus. One patient developed an anastomotic leak in the postoperative period, requiring re-exploration. The median postoperative length of stay was 7 days (range, 4–29 days), three patients required readmissions within 30 days, and there were no operative mortalities The median follow-up time for was 13.7 months (range, 3–38 months). The median overall survival was 30.6 months with a median disease-free survival of 25 months.

Conclusions: We report that HIPEC with PLD following maximal cytoreduction in patients with advanced abdominal-only gastrointestinal or gynecologic malignancies is well tolerated. Encouraging survival after cytoreduction and HIPEC with PLD suggest that a phase II trial to verify activity is indicated.

Key Words: Phase I • Doxorubicin • Hyperthermia • Cytoreduction • Liposomal




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
P. H. Sugarbaker
Getting Chemotherapy into the Cancerous Tissue
Ann. Surg. Oncol., November 1, 2008; 15(11): 3320 - 3320.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
L. E. Harrison
Pharmacologic Study of Pegylated Liposomal Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy
Ann. Surg. Oncol., November 1, 2008; 15(11): 3321 - 3321.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.